N.B. The English text is an in-house translated summary of the original Swedish text and should only be construed as a brief notification service to non-domestic shareholders. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.
The shareholders of Chordate Medical Holding AB (publ) are hereby summoned to the Extraordinary General Meeting on October 5th, 2021.
Matters of the Extraordinary General Meeting are listed below. The notice in its entirety and postal voting form will be made available in English on the company website.
- Election of chairman
- Establishment and approval of the ballot paper
- Selection of one or two adjusters
- Examination of whether the Extraordinary General Meeting has been duly convened
- Approval of agenda
- Determination of fees to the board
- Election of a board member
- The Board's proposal for a long-term incentive program 2021
- Establishment of a nomination committee
For more information about the full Notice of Extraordinary General Meeting, please read the Swedish version (or the English version, when made available on the company website), or contact the company.
This disclosure was submitted for publication, through the contact person below, on September 20th, 2021, at 14:30 am CET.
For more information, please contact:
Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77
The following documents can be retrieved from beQuoted
Notice-of-Extraordinary-General-Meeting-of-Chordate-Medical-.pdf
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at https://www.chordate.com/en/
